

EMOSIS reinforces its Intellectual Property and scientific expertise

Strasbourg, November 22nd 2018

The French innovative Medical Device start-up Emosis, specializing in cytomolecular diagnostics of thrombosis and hemostasis disorders, is reinforcing its intellectual property on HIT Confirm®, Emosis first test kit which was recently launched in Europe (CE Mark).

The company was granted a US patent “Platelet Analysis System” (US10, 012,658 B2), and the PCT of the patent “Heparin-induced thrombocytopenia test” (PCT/IB2018/052179) was recently published.

Heparin-induced thrombocytopenia (HIT) is a potentially lethal disorder caused by heparin, the most prescribed injectable anticoagulant worldwide, and the patent covers a rapid, on

demand, functional test to confirm the diagnosis of that condition.

Rapid and accurate diagnosis of HIT is of critical clinical importance because of an initial 6% daily risk of thromboembolism, amputation and death, while misdiagnosis. In contrast, unnecessarily exposes patients without HIT to costly alternative anticoagulants and their attendant 1% daily risk of major bleeding (Cuker 2014).

Dr. Frederic Allemand, Emosis CEO, declared: “These patents reinforce Emosis intellectual property arsenal and confirm the innovativeness of the cytomolecular approach in diagnosing hemostasis and thrombosis disorders.

ABOUT EMOSIS

Emosis is an innovative medical device company specializing in cytomolecular diagnostics of hemostasis and thrombosis disorders. The company is dedicated to the clinically-centered development, marketing and commercialization of first-in-class, on-demand and user-friendly assays, Emo-tests, to be routinely performed on the rapidly growing new generation of low cost and operator friendly flow cytometers. Emo-tests aim to inform physician medical decision with respect to bleeding or clotting events (or risk of) in a broad range of clinical settings, encompassing cardiovascular and neurovascular diseases, cancer, pregnancy, and pharmacological and non-pharmacological therapy management.

